Inactivation of prenyltransferase inhibitors by S-methylation catalyzed by the methyltransferases TMT1A (METTL7A) and TMT1B (METTL7B)

The thiol methyltransferases TMT1A and TMT1B (formerly METTL7A and METTL7B) metabolize thiol-containing compounds, but their substrate range and effects on drug activity remain incompletely defined. Here, we investigated whether these enzymes methylate protein prenyltransferase inhibitors and alter cellular sensitivity to these compounds. Mass spectrometry identified several thiol-containing farnesyltransferase and geranylgeranyltransferase inhibitors as substrates of both enzymes, whereas other thiol-containing inhibitors showed no detectable methylation. In HT1080 fibrosarcoma cells, TMT1A or TMT1B overexpression conferred resistance to several geranylgeranyltransferase inhibitors and attenuated drug-induced cell-cycle arrest. Pharmacological inhibition of TMT1A with 2,3-Dichloro-α-methylbenzylamine (DCMB, LY-78335) reversed resistance and restored cell-cycle arrest in TMT1A-expressing cells. These findings expand the known substrate range of TMT1A and TMT1B and support TMT-dependent methylation as a mechanism that reduces the cellular activity of susceptible prenyltransferase inhibitors.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.12.766183
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Inactivation of prenyltransferase inhibitors by S-methylation catalyzed by the methyltransferases TMT1A (METTL7A) and TMT1B (METTL7B)

Lisa M. Miller Jenkins, Pedro J. Batista, William J.E. Frye, Michael M. Gottesman et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Pharmacogenetics and Drug Metabolism
preprint

Inactivation of prenyltransferase inhibitors by S-methylation catalyzed by the methyltransferases TMT1A (METTL7A) and TMT1B (METTL7B)

Lisa M. Miller Jenkins, Pedro J. Batista, William J.E. Frye, Michael M. Gottesman, Robert W. Robey, Crystal C. Lipsey, Connor P. Jewell, Zachary E. Paikin, Lucia A. Lavallee, Michelle A. Kwarteng, Diya V. Jariwala
preprint en

Abstract

The thiol methyltransferases TMT1A and TMT1B (formerly METTL7A and METTL7B) metabolize thiol-containing compounds, but their substrate range and effects on drug activity remain incompletely defined. Here, we investigated whether these enzymes methylate protein prenyltransferase inhibitors and alter cellular sensitivity to these compounds. Mass spectrometry identified several thiol-containing farnesyltransferase and geranylgeranyltransferase inhibitors as substrates of both enzymes, whereas other thiol-containing inhibitors showed no detectable methylation. In HT1080 fibrosarcoma cells, TMT1A or TMT1B overexpression conferred resistance to several geranylgeranyltransferase inhibitors and attenuated drug-induced cell-cycle arrest. Pharmacological inhibition of TMT1A with 2,3-Dichloro-α-methylbenzylamine (DCMB, LY-78335) reversed resistance and restored cell-cycle arrest in TMT1A-expressing cells. These findings expand the known substrate range of TMT1A and TMT1B and support TMT-dependent methylation as a mechanism that reduces the cellular activity of susceptible prenyltransferase inhibitors.

bioRxiv (Cold Spring Harbor Laboratory)
National Institutes of Health (US)
U.S. Department of Health and Human Services, National Institutes of Health
Good health and well-being
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon